article thumbnail

A perfect storm for biotech stocks

World of DTC Marketing

According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. It dropped more than 15% in 2016 and followed that up with a 44% rise in 2017.

article thumbnail

A scientific approach to irrational consumer choices

World of DTC Marketing

GOOD MORNING: The FDA is taking a scientific approach to evaluating direct-to-consumer (DTC) drug advertising, focusing on measuring consumer perceptions of the information presented in ads. Presenting quantitative information increased participants’ gist and verbatim recall of drug efficacy. ” Uh…no.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CHMP to review MAA for geographic atrophy treatment

European Pharmaceutical Review

“This acceptance of our EU Marketing Authorisation Application is a key milestone in our global effort to help patients living with GA, a leading cause of blindness worldwide. FDA approves first treatment for geographic atrophy Avacincaptad Pegol Avacincaptad pegol (ACP) is a complement C5 protein inhibitor.

article thumbnail

Could digital therapeutics provide a solution against opioid abuse?

pharmaphorum

The most common solutions today for pain relief are non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, meaning that standard treatments have not changed for a number of years. This leads to psychological harm becoming a significant factor in chronic pain, alongside the physical symptoms. The potential for a digital solution.

article thumbnail

Innoviva enters agreement to acquire La Jolla Pharmaceutical Company

Pharmaceutical Technology

The lead product of the company, Giapreza (angiotensin II) obtained the Food and Drug Administration (FDA) approval in December 2017. La Jolla focuses on marketing innovative treatments that can enhance outcomes in patients with life-threatening diseases.

article thumbnail

Three-dose vaccine prevents HIV patients getting hepatitis B

European Pharmaceutical Review

A two-dose version of the vaccine was approved by the US Food and Drug Administration (FDA) in 2017. It causes severe hepatitis B infection that can lead to progressive liver disease. At the time, limited evidence was available surrounding its ability to protect people living with HIV.

article thumbnail

Shorter timelines, evolving strategies: Four key trends in regulatory approvals of new medicines

Clarivate

Increased collaboration between regulatory agencies also appears to be having a positive impact on the roll out of new drugs. The following blog post summarizes key findings from the latest CIRS R&D Briefing, New drug approvals in six major authorities 2012-2021. FDA continues to approve the most NASs. Changes in company strategy.